SCHEMBL2903498

SCHEMBL2903498

COc1cnc(-n2c(=S)[nH]c3cc(C(=O)NCc4ccc(C(=O)c5ccccc5)cc4)ccc3c2=O)nc1OC

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.56
▸ MEN1 O00255 7/20 0.54
▸ KMT2A Q03164 7/20 0.54
▸ ALDH1A1 P00352 7/20 0.52
▸ MAPT P10636 6/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ RXFP1 Q9HBX9 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.48
▸ GLA P06280 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ TP53 P04637 1/20 0.47
▸ EGLN3 Q9H6Z9 2/20 0.47
▸ TSHR P16473 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901113 0.95 MEN1 (0.54) USP2MEN1KMT2AALDH1A1MAPT
SCHEMBL2895179 0.91 EGLN3 (0.57) USP2MEN1KMT2AALDH1A1MAPT
SCHEMBL2902346 0.90 KMT2A (0.58) USP2MEN1KMT2AALDH1A1MAPT
SCHEMBL2913829 0.89 KMT2A (0.57) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL2897948 0.88 MEN1 (0.70) USP2MEN1KMT2AALDH1A1MAPT
SCHEMBL2901148 0.87 KMT2A (0.55) USP2MEN1KMT2AALDH1A1MAPT
SCHEMBL2903505 0.87 MEN1 (0.52) USP2MEN1KMT2AALDH1A1MAPT
SCHEMBL2914566 0.86 KMT2A (0.49) USP2MEN1KMT2AALDH1A1MAPT
SCHEMBL2919143 0.86 THRB (0.53) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL13037502 0.85 ALDH1A1 (0.48) USP2MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US claimed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP claimed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO claimed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 USP2 507/4885MEN1 4104/4885KMT2A 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback